D International Symposium: Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop Fundación Ramón Areces
GENERAL INFORMATION DATES OCTOBER 18th 20th VENUE University of Navarra. Pamplona, Spain Modern art museum designed by Rafael Moneo in the University of Navarra main campus (inaugurated in Feb 2015) ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN SYMPOSIUM COORDINATORS Dr. Ignacio Melero Centro de Investigación Médica Aplicada. Clínica Universidad de Navarra. Pamplona Dr. Juan José Lasarte Centro de Investigación Médica Aplicada. Pamplona REGISTRATIONS (FREE OF CHARGE): simposioareces@unav.es
PROGRAM 18 th October 16.00 16.30 Opening Chair: Jesús San Miguel and Juan José Lasarte 16.30 17.15 Ronald Levy Targeting the Tumor and Targeting the Host. Stanford University Medical Center, Stanford, United States 17.15 18.00 Drew Pardoll Protumorogenic immunity: the dark side of the immune system. Johns Hopkins Medical Institutions, Baltimore, United States 18.00 19.00 BREAK Chair: Ignacio Gil Bazo and Ignacio Melero 19.00 19.45 Jim Allison Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities. MD Anderson Cancer center. Houston. United States 19.45 20.30 Antoni Ribas Melanoma response and resistance to PD 1 blockade UCLA Medical Center. Los Angeles, California, United States 19 th October Chair: Juan José Lasarte 08.30 09.15 George Coukos Understanding tumor microenvironment to optimize immunotherapy. Lessons from ovarian cancer University of Laussane Medical center, Switzerland 09.15 10.00 Ignacio Melero CD137 and friends in immunotherapy combinations. Centro para la Investigación Médica Aplicada Clínica Universidad de Navarra, Pamplona, Spain 10.00 10.45 Sergio Quezada Immune Regulation at the Tumour Site. UCL Cancer Institute, London, United Kingdom 10.45 11.00 Questions 11.00 11.15 BREAK
Chair: José Luis Pérez Gracia 11.15 12.00 Suzanne Topalian PD 1 pathway blockade: a common denominator treatment approach mediates a personalized response. Johns Hopkins Medical Institutions, Baltimore, United States 12.00 12.45 Mario Sznol Immune Therapy of Advanced Melanoma based on Immune Checkpoint Inhibitors. School of medicine of Yale. New Haven. United States 12.45 13.30 Pam Sharma Immunotherapy frontiers against prostate and bladder cancer. MD Anderson Cancer Center. Houston. United States 13.30 13.45 Questions 13.45 15.30 LUNCH Chair: Pedro Berraondo 15.30 16.15 Tim Chan Cancer genomes and immunotherapy efficacy. Memorial Sloan Kettering Cancer Center, New York city, United States 16.15 17.00 Sandra Demaria Mechanisms of synergy of radiotherapy with antibodies targeting negative immune regulators in the tumor microenvironment. New York University School of Medicine. New York city, United States 17.00 17.45 Janice Taube Tumor markers of response and resistance to PD 1/PD L1 checkpoint blockade. Johns Hopkins Hospital. Baltimore. United States 17.45 18.00 Questions 20 th October Chair: Ignacio Melero 08.30 9.15 Cornelis Melief Therapeutic cancer vaccines and their application in combination treatment of cancer Leiden University Medical Centre. ISA Pharmaceuticals. Leiden, The Netherlands 9.15 10.00 Caroline Robert Melanoma management : New Treatments and new Toxicities Institute Gustave Roussy, Villejuif, France 10.00 10.45 John Haanen Checkpoint inhibitors: who should we treat? The Netherlands Cancer Research Institute. Amsterdam, The Netherlands 10.45 11.00 Questions 11.00 11.15 BREAK
Chair: Pablo Sarobe 11.15 12.00 Francisco Sánchez Madrid Leukocyte activation receptor CD69 and ligands: Immunoregulatory role in inflammatory processes. Hospital de la Princesa. Madrid, Spain 12.00 12.45 Juan José Lasarte FOXP3 as a target for Immunotherapy. Centro para la Investigación Médica Aplicada. Pamplona, Spain 12.45 13.30 María Luisa Toribio Therapeutic antibody targeting of human T cell acute lymphoblastic leukemia initiang cells. Centro de Biología Molecular Severo Ochoa. Madrid, Spain 13.30 14.15 Mario Colombo Multiple layers of immunoregulation: the myeloid connection. Instituto Nazionale Tumori Experimental Oncology. Milan, Italy 14.15 14.30 Questions 14.30 16.00 LUNCH Chair: Mario Colombo 16.00 16.45 Rienk Offringa "A rational approach towards implementation of immunotherapy for pancreatic ductal adenocarcinoma. German Cancer Research Center, Heidelberg, Germany 16.45 17.30 Christian Ottensmaier Genomic assessment of tumour immune profiles in head and neck cancer. University of Southampton School of Medicine, Southampton, United Kingdom 17.30 17.45 Questions 17.45 18.00 BREAK Chair: Rienk Offringa 18.00 18.45 Paolo Ascierto Combining checkpoint inhibition maximizing the body s immune response to cancers. Fondazione Pascale Istituto Nazionale Tumori di Napoli, Italy 18.45 19.30 Martin Glennie Designing immunostimulatory anti TNFR mab to promote anti cancer immunity. University of Southampton School of Medicine, Southampton, United Kingdom 19.30 20.15 Questions 20.15 Closing remarks
Additional sponsors: ASTRA ZENECA BRISTOL MYERS SQUIBBS MSD ROCHE With the collaboration: CIMA CUN EUFP7 IACT GETICA GEIT REINCA IdiSNA